top of page

No-Exam Term Life Insurance with Crohn's or Ulcerative Colitis: What to Expect

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Crohn's and ulcerative colitis vary widely. Accelerated/no-exam programs may screen them out, while traditional underwriting often looks closely at flare history, meds, and complications.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

IBD Is Underwritten by Severity + Stability

Flare frequency, hospitalizations, and recent stability

Medication history and whether treatment has escalated

Surgeries, complications, and ongoing GI follow-up

Inflammatory bowel disease isn't one diagnosis with one outcome, and underwriters approach it that way. Two people can both have Crohn's disease and have completely different severity levels, disease behaviors, and stability histories -- which is why underwriting asks for the details rather than making a blanket decision based on the diagnosis label alone. Crohn's specifically has three recognized disease phenotypes that carry different expected risk trajectories: inflammatory (active disease without structural complications), stricturing (bowel narrowing that may require procedural or surgical intervention), and penetrating or fistulizing disease (abnormal connections between bowel segments or to adjacent structures). Each phenotype is evaluated differently, and an underwriter reviewing your records will note which pattern your disease has followed because that history directly affects the expected future complication and hospitalization risk.

Many accelerated and no-exam programs use quick filters that may not offer instant approval for IBD, but that outcome reflects the program's filter design rather than a conclusion about your insurability, and traditional underwriting is usually where the real options are. One of the clearest signals underwriters use to assess disease severity is the medication tier the applicant is currently on, because the escalation sequence in Crohn's management reliably reflects how well earlier therapies controlled the disease. Moving from 5-ASA agents like mesalamine through immunomodulators like azathioprine and 6-mercaptopurine, to anti-TNF biologics like adalimumab and infliximab, to anti-integrin agents like vedolizumab, and finally to anti-IL-12/23 therapy like ustekinumab signals increasing disease burden at each tier. An applicant on a biologic is not automatically declined, but the medication tier communicates disease history to underwriters more reliably than a flare count alone.

Underwriters typically look at recent stability: when your last flare occurred, whether you've been hospitalized for disease activity, whether there have been complications or surgeries, and how consistent your specialist follow-up has been. Surgical history is a strong underwriting flag -- a bowel resection or ostomy in the Crohn's history typically triggers a records request regardless of how stable things are at the time of application, because it signals the disease progressed to a point requiring structural intervention. Ulcerative colitis, while also classified as IBD, is underwritten differently from Crohn's: UC is limited to the colon, and a colectomy can actually be curative, which underwriters may view as a favorable factor in a way that bowel resection in Crohn's disease -- which is not curable by surgery -- is not.

If your condition has been stable with routine specialist follow-up and you're at an earlier tier of the medication sequence, you may have more options than online research suggests. Frequent or recent corticosteroid use is itself a signal underwriters note separately from the maintenance medication -- it indicates active, recurring disease rather than sustained remission, because corticosteroids are typically prescribed to manage flares rather than maintain long-term control. If you've had recent flares requiring steroids, a recent escalation to a higher-tier medication, or a recent hospitalization for disease activity, the carrier may request attending physician records or delay a decision until the clinical picture has stabilized over a defined period.

Before you apply, have a clear timeline ready: initial diagnosis date, disease phenotype if you know it, most recent flare date and any associated hospitalization, current medications and how long you've been on each, and any surgical history including the reason for and outcome of each procedure. Clear, organized information is the difference between a quick decision and weeks of back-and-forth while a carrier works to reconstruct your disease history from incomplete disclosures -- and consistent, accurate inputs across every quote you request ensure that pricing comparisons reflect real carrier differences rather than differences in what each quote assumed.

For the overall term life guide and the different underwriting paths, see: https://www.careproinsurance.com/instant-term-life-insurance

For education only. Not intended as legal, medical, or tax guidance. Estimates shown during quoting are preliminary and may be modified by underwriting.

Frequently Asked Questions

Can I get no-exam term life insurance with Crohn's disease?

Sometimes. Many accelerated/no-exam programs are less flexible with IBD, but traditional underwriting may offer options depending on severity and stability. Carrier rules vary.

What Crohn's or UC details do underwriters usually ask about?

Common questions include flare frequency, hospitalizations, medications, any surgeries, complications, and how stable the condition has been recently.

Do biologics or steroids affect life insurance underwriting?

They can. Underwriters may view certain medications as a signal of severity or instability. Outcomes depend on your overall control and the carrier's guidelines.

Will I need a medical exam with IBD?

Not always, but more detailed underwriting and records review are common. Requirements depend on the carrier, coverage amount, and your history.

How can I keep IBD-related quotes accurate?

Use a consistent, honest summary of your history across quotes: last flare date, meds, hospitalizations, and any surgeries. Quotes can change if underwriting assumptions differ.

What are the three Crohn's disease phenotypes, and why do they matter to underwriters?

The three phenotypes are inflammatory (active disease without structural complications), stricturing (bowel narrowing), and penetrating or fistulizing (abnormal bowel connections). Each carries a different expected disease trajectory and complication risk. Underwriters note which pattern your disease has followed because stricturing and penetrating disease signal a higher likelihood of future surgical intervention than inflammatory disease alone.

How is ulcerative colitis underwritten differently from Crohn's disease?

UC is limited to the colon and can be cured surgically through colectomy -- a factor underwriters may view favorably if surgery produced durable remission. Crohn's disease can affect any part of the GI tract and is not curable by surgery, so bowel resection in a Crohn's history is evaluated as a severity signal rather than a potentially positive outcome.

Does frequent or recent corticosteroid use for IBD affect how an underwriter evaluates my application?

Yes. Corticosteroids are typically used to manage active flares rather than for long-term maintenance, so frequent or recent steroid courses signal recurring disease activity rather than stable remission. Underwriters distinguish between applicants on stable long-term maintenance regimens and those who have needed repeated steroid courses -- the latter pattern suggests the maintenance therapy hasn't been fully controlling the disease.

Get Covered With The Right Plan

Explain why IBD can trigger declines in accelerated programs and what underwriters evaluate when the case moves to traditional review.

Compare term life options

bottom of page